Khadija Saeed

April 2, 2026, 8:54 AM EDT. Veeva Systems' share price has fallen to around $172.74, down 23.7% over the past year, raising questions about its value. Despite recent weakness, a discounted cash flow (DCF) analysis estimates the stock's intrinsic value at roughly $268.90, suggesting it is undervalued by 35.8%. The company, active in healthcare software and life sciences partnerships, reported free cash flow of $1.39 billion in the past twelve months. Analysts project growth to $2.43 billion by 2031, supporting bullish long-term prospects. Veeva's price-to-earnings (P/E) ratio also factors into valuation, reflecting market expectations of earnings growth and risk. Investor sentiment fluctuates due to sector dynamics, but the DCF model indicates potential upside from current levels.